Short Interest in Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Increases By 841.9%

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 40,500 shares, a growth of 841.9% from the November 30th total of 4,300 shares. Based on an average daily volume of 171,400 shares, the short-interest ratio is currently 0.2 days.

Inhibitor Therapeutics Stock Up 19.5 %

Shares of INTI traded up $0.01 during mid-day trading on Thursday, reaching $0.08. The company had a trading volume of 2,000 shares, compared to its average volume of 29,786. Inhibitor Therapeutics has a 52-week low of $0.03 and a 52-week high of $0.14. The stock has a 50 day moving average of $0.08 and a two-hundred day moving average of $0.08. The stock has a market capitalization of $13.51 million, a P/E ratio of -7.84 and a beta of -0.61.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.